Alpha-synuclein oligomers detection by proximity ligation assay in skin biopsy is a biomarker for Parkinson’s disease
Objective: To assess the presence of oligomeric alpha-synuclein (αSyn), an early pathogenic species, in skin nerve fibers of patients with Parkinson’s disease (PD) and atypical…Pharmacokinetic–pharmacodynamics of levodopa/carbidopa following subcutaneous infusion with ND0612: Results from the BeyoND pharmacokinetic substudy
Objective: To evaluate the pharmacokinetic–pharmacodynamic relationships between levodopa plasma exposure and motor treatment response in patients with Parkinson’s disease (PD) treated with ND0612 and adjunct…Study Design to Assess the Effect of Opicapone on Levodopa PK at Different Levodopa-Optimized Treatment Regimens in Parkinson’s Disease Patients
Objective: This study was designed to assess the effect of opicapone (OPC) 50 mg once daily (QD) on levodopa (L-DOPA) pharmacokinetics (PK) in different L-DOPA/carbidopa…PARK-BAND training program for Parkinson’s disease in clinical settings: A feasibility study.
Objective: To describe indicators of feasibility, including acceptability and safety, of Power training (PT) in Parkinson’s Disease (PD). Background: PT is a specific method of…Remote Art Therapy is feasible and may benefit individuals with Parkinson’s disease
Objective: To evaluate the feasibility of remote art therapy (rAT) for patients with Parkinson’s disease (PD), and compare psychosocial outcomes to in-person AT (ipAT). Background:…Validation of the Neuroprotective Potential of SLP-2 against alpha-synuclein neuropathology in a Mouse Model of Parkinson’s Disease
Objective: We aim to validate the neuroprotective potential of SLP-2 against α-syn neuropathology and neurodegeneration of dopaminergic neurons in a mouse model of Parkinson’s disease.…Directional steering in subthalamic deep brain stimulation for Parkinson’s disease: the Berlin experience
Objective: To review the use of directional current steering in a Berlin cohort implanted with segmented leads between 2016-2019. Background: The dorsolateral area of the subthalamic…DOPAMINERGIC AND NON-DOPAMINERGIC TREATMENT AFTER DEEP BRAIN STIMULATION (DBS) IN PARKINSON DISEASE (PD). IMPORTANCE OF NON MOTOR SYMPTOMS (NMS)
Objective: To analyse global pharmacological adjustment after Deep Brain Stimulation (DBS) in Parkinson's Disease (PD) patients, and secondarily its relation with Non Motor Symptoms (NMS).…Real-world characteristics of advanced Parkinson’s disease patients initiating carbidopa/levodopa enteral suspension
Objective: To describe the real-world characteristics of advanced Parkinson’s disease (APD) patients initiating carbidopa/levodopa enteral suspension (CLES) therapy in USA Background: CLES is an FDA…Attitudes on therapy-associated risks in individuals with multiple system atrophy and Parkinson’s disease and their views on aspects of clinical trials
Objective: To assess risk attitudes of patients suffering from multiple system atrophy (MSA) and Parkinson’s disease (PD) on future disease-modifying therapies as well as related…
- « Previous Page
- 1
- …
- 372
- 373
- 374
- 375
- 376
- …
- 436
- Next Page »